New CEO Camillo Pane says the 40-plus beauty brands picked up from P&G position Coty as a “challenger” in global beauty. The firm aims to achieve a “best-in-class profit margin and cash flow conversion model,” with projected growth acceleration in the second half of fiscal 2017.
[Coty Inc.] is officially the world’s third-largest beauty company and No. 1 global fragrance player with the completion of its merger with Procter & Gamble Co.’s specialty beauty business, announced Oct. 3.
“It is my great privilege to take over the reins of leadership at such a transformational moment,” says new CEO...
Curve Biosciences has developed a "Whole-Body Intelligence" platform using cfDNA from blood to monitor chronic diseases, starting with the liver. Focused on liver cirrhosis and MASH, the company aims to aid in treatment decisions and plans to expand into monitoring other organs.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
L’Oréal and Galderma have signed a memorandum of understanding to collaborate on complementary research projects to discover ‘new avenues and accelerate innovation’ in the field of dermatology. L’Oreal has arranged to purchase a 10% stake in its partner.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
